Tobacco use as a screener for Clostridium difficile infection outcomes.

Isolation of Clostridium Difficile from Turkey and Ostrich Meat Sold in Meat Stores if Isfahan City

Clostridium difficileisa binding warm-positive rod and anaerobic organism, which was first described in 1935 as Bacillus difficile. Epidemiology of CDI has changed considerably on 2000. Occurrence and severity of the disease  including ulcerative colitis(inflammation of the colon), colectomy(colon section) and mortality had increased. Recent studies have reported Clostridium difficile prevalenc...

Isolation of Clostridium Difficile from Turkey and Ostrich Meat Sold in Meat Stores if Isfahan City

Clostridium difficileisa binding warm-positive rod and anaerobic organism, which was first described in 1935 as Bacillus difficile. Epidemiology of CDI has changed considerably on 2000. Occurrence and severity of the disease  including ulcerative colitis(inflammation of the colon), colectomy(colon section) and mortality had increased. Recent studies have reported Clostridium difficile prevalenc...

مروری بر مطالعات اپیدمیولوژیک عفونت‌های ناشی از کلستریدیوم دیفیسیل

Clostridium difficile (C. difficile) is an important factor in the development of the gastrointestinal diseases because of irrational antibiotic prescription and antimicrobial resistance. In the past, this bacterium was introduced as an agent of the infection in the hospitals called "hospital acquired Clostridium difficile infection". This infection is a main cause of morbidity and mortality in...

Risk factors for Clostridium difficile infection in HIV-infected patients

BACKGROUND Clostridium difficile infection is a healthcare-associated infection resulting in significant morbidity. Although immunosuppression is associated with Clostridium difficile infection acquisition and adverse outcomes, the epidemiology of Clostridium difficile infection in HIV-infected patients has been little studied in the era of antiretroviral therapy. This study identifies the risk...

467Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections